Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

MDMB-CHMICA

A very potent synthetic cannabinoid, controlled across the Union since 2017 (28 deaths and 25 acute intoxications reported).

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₃H₃₂N₂O₃

CAS 1971007-95-0

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
384.51 g/mol

Updated on

In plain terms

MDMB-CHMICA is a synthetic cannabinoid that appeared on the drug market in Europe in 2014. It activates CB1 and CB2 receptors more strongly than THC. Eight Member States of the Union reported 28 deaths and 25 acute intoxications in which it was detected; it has been controlled across the Union since 2017.

Receptors and activity

Target network

CB1AgonistKi = 0.9 nM · human[3H]CP-55940 displacement, human CB1
  • Activates

The lower the cited value, the closer the target sits to MDMB-CHMICA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MDMB-CHMICA.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1AgonistKi = 0.9 nM · human84 out of 100

    Sommer et al. 2026, Addiction (new tab) · [3H]CP-55940 displacement, human CB1

  2. CB2Agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

MDMB-CHMICA is an indole-3-carboxamide whose head is the methyl ester of L-tert-leucine and whose tail is a cyclohexylmethyl group. Banister et al. (2016) synthesised and tested it: it acts as a potent, highly efficacious agonist at CB1 and CB2 receptors, with a potency greater than that of Δ9-THC and of earlier generations of SCRAs (EC50 of 0.45 to 36 nM at CB1 across all compounds in the study). It had been available on the Union market since at least August 2014 and had been detected in 23 Member States; eight Member States had reported 28 deaths and 25 acute intoxications in which it was detected (Implementing Decision (EU) 2017/369 of 27 February 2017, which subjects it to control measures across the Union). It has been in Schedule II of the 1971 Convention since CND decision 60/9 (16 March 2017) and is in Annex III of the French list of narcotics.

Key sources.

History

Source
Designer-drug market: available in the Union since at least August 2014, bulk powders produced by chemical companies based in China according to Implementing Decision (EU) 2017/369

Origin

Laboratory synthesis

Indole-3-carboxamide: an indole substituted on the nitrogen by a cyclohexylmethyl group and, at position 3, by a carboxamide linked to the methyl ester of L-tert-leucine

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

References

  1. Banister · ACS Chem Neurosci 2016 (new tab)PMID 27421060
  2. Sommer · Addiction 2026 (new tab)PMID 41423817

Identifiers

Names

IUPAC name
methyl (2S)-2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate
Other names
MMB-CHMINACA

Identifiers

Formula
C₂₃H₃₂N₂O₃
CAS
1971007-95-0
PubChem CID
125181404(new tab)
InChIKey
SRJKCVHWIDFUBO-HXUWFJFHSA-N
SMILES
CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=CN(C2=CC=CC=C21)CC3CCCCC3

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.